InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,298.94
(
0.59%
)
US TECH 100
18,301.64
(
0.86%
)
Dow Jones
39,058.32
(
-0.02%
)
Brent Oil
81.92
(
0.74%
)
Bitcoin
68,966.30
(
1.52%
)
Post# of 251931
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119687
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 179536

Thursday, 06/19/2014 5:29:33 PM

Thursday, June 19, 2014 5:29:33 PM

Post# of 251931
Correct! DRTX’s Dalvance has non-patent Orange Book exclusivity until May 23, 2024. Dalvance was approved by the FDA on 5/23/14; it received 5 years of NCE exclusivity and an additional 5 years of ‘GAIN’ exclusivity as a novel antibiotic—10 years of exclusivity in all.

More discussion:
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2014/06/dalvance-gains-bonus-exclusivity-fda-grants-the-first-period-of-gain-act-exclusivity.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up